Ļć½¶Ö±²„ School of Medicine to Announce More Than $20 Million in New Research Grants
The Texas Tech University Health Sciences Center (Ļć½¶Ö±²„) School of Medicine announced $20.5 million in new research funding this year.
Steven Berk, M.D., Ļć½¶Ö±²„ executive vice president, provost and School of Medicine dean, said these grants focus in areas such as cancer, alcoholism, pain management, neuroscience and infectious diseases.
Steven Berk, M.D., Ļć½¶Ö±²„ executive vice president, provost and School of Medicine Dean
āThe School of Medicine is dedicated to providing the best care and one way to achieve that is through research,ā Berk said. āResearch leads to new knowledge and discoveries which allows our experts to seek new treatments and develop new medications. Research goes hand-in-hand with better technology, cures and teaching future physicians.ā
The National Institutes of Health (NIH), including the National Cancer Institute (NCI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Neurological Disorders and Stroke (NINDS), the Department of Defense (DOD), along with others from the National Science Foundation (NSF), and the Cancer Prevention Research Institute of Texas (CPRIT), awarded the grants.
President Tedd L. Mitchell, M.D., Texas Tech University System Interim Chancellor and Ļć½¶Ö±²„ President
āThis celebration is to recognize the outstanding work of our investigators in cancer, vaccine and drug development, pain management, aging, infectious diseases and other fields,ā Texas Tech University System Interim Chancellor and Ļć½¶Ö±²„ President Tedd L. Mitchell, M.D., said. āThey have the full support of our leadership and our faculty. Externally funded peer-reviewed research at Ļć½¶Ö±²„ is truly excellent and is growing rapidly. The discovery of new knowledge has always been a core mission.ā
Quentin Smith, Ph.D., Ļć½¶Ö±²„ Senior Vice President of Research
Grants include:
Sanjay Awasthi, M.D., Department of Defense, $1,147,500.00 over three years
āPrevention of Breast Cancer by Haploinsufficiency of RALBP1ā
Patrick Reynolds, M.D., Ph.D., and Min Kang, Pharm.D., NIH/NCI, $2 million over five years, āMYC Activation in Tumor Progression of Neuroblastomaā and also NIH/NCI, $1,622,266 over three years, āCharacterization of a panel of neuroblastoma patient-derived models for preclinical therapeutic studiesā
Reynolds, also received an NIH/NCI, $1,749,940 over five years
āAlternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targetsā
H. Liang, Ph.D., CPRIT, $200,000 over two years
āPolymer nanodiscs: Novel lipoprotein-mimicking nanocarriers with high stability and long circulation time for enhanced anticancer drug deliveryā
Yangzom Bhutia, Ph.D., NIH, $153,000.00
āCarbidopa as an inhibitor of the TrpT/IDO1 complex: Potential for use as an immunotherapy agent?ā
H. Liang, Ph.D., NSF, $457,931 over three years
āNanostructure engineering is another approach toward membrane-active antimicrobials with desirable activity and selectivityā
Lan Guan, Ph.D., NIH NIGMS, $1,300,500 over five years
āIntegrated approaches to symport mechanisms of membrane transportersā
Luis Cuello, Ph.D., NIH, $1,247,868 over five years
āHigh-resolution crystallographic and functional studies of potassium channel functionā
Volker Neugebauer, Ph.D.,NIH/NINDS, $1,536,123.00 over five years
āStress-induced descending facilitation from amygdala kappa opioid receptors in functional painā
JosƩe Guindon, Ph.D., NIH from NIDA, $691,332.00 over five years
āMechanisms of cannabinoid toleranceā
Ion Bobulescu, M.D., NIH/NIDDK, 1,047,717.00
āRole of gut bacteria and renal lipids in obesity-related kidney diseaseā
Susan Bergeson, Ph.D., and Ted Reid, Ph.D., NIH/NIAAA, $60,000 over one year, āDevelopment of Tetracycline Analogs for Alcohol Use Disorder Treatment,ā and NIH/NIAAA, $1,639,120.00 over five years, āChemically modified minocycline for treatment of alcohol use disorderā
Andrey Karamyshev, Ph.D.,NIH/NINDS,$153,000.00 over two years
āIdentification of Translational Regulators of Alpha-Synuclein Folding and Aggregationā
Sam Prien, Ph.D., NSF, $50,000
āA non-invasive technique for embryo assessmentā
View the full press conference through Facebook live at .